16 December, 2014
Chordate Medical’s treatment system for rhinitis, Chordate Rhinitis Controller, received CE-mark for non-allergic Rhinitis (NAR) treatment today by the notified body Intertek.
If you want to read our press releases, there are available in the Investor Relations section or by clicking the link below.
For questions about Chordate's share price or other investment-related topics, please see if the answer is here.
For questions about the medical effects of the K.O.S treatment, please see if the answer is here.
To get in touch with Chordate regarding other questions, use the adjecent form. We do our best to respond as quickly as possible.